tried to improve the prognostic value of the IPI and developed a prognostic model combining β2M and IPI variables (β2M‐IPI) in DLBCL patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)‐based regimes.15 This evidence concerns the gene B2M and diffuse large B-cell lymphoma.